

## **Curriculum Vitae**

### **Personal Data:**

Name: Kristen Mahoney Shannon, MS, CGC  
Address: 6 Brenda Ln.  
Burlington, MA 01803  
Phone: (617) 968-3898  
Citizenship: USA

### **Education:**

Undergraduate: College of the Holy Cross  
1 College St.  
Worcester, MA 01610  
BA, Biology, 1991

Graduate: Sarah Lawrence College  
1 Mead Way  
Yonkers, NY 10708  
MS, Human Genetics, 1996

### **Certification**

American Board of Genetic Counseling, 1999.

### **License Information**

Commonwealth of Massachusetts. Board of Registration of Genetic Counselors, License # GC042  
State of New Hampshire. Office of Licensed Allied Health Professionals, License #0044.

### **Academic Appointments**

Professor of Genetic Counseling  
School of Health and Rehabilitation Sciences  
MGH Institute of Health Professions  
2017 - present

## **Employment Experience**

**Massachusetts General Hospital** 01/21-present  
55 Fruit St.  
Boston, MA 02114  
*Director, Cancer Center Genetics Program*  
*Director, Genetic Counseling, Department of Medicine*  
-Oversees all administrative aspects of the MGH Cancer Genetics Program.  
-Supervises Program Managers to ensure quality operations at all MGH facilities and at all Network Affiliations.  
-Works collaboratively with the Clinical Directors of the Cancer Genetics programs to ensure program direction and patient care provided is appropriate.  
-Works collaboratively with Cancer Genetics physicians and staff to move forward the research initiatives of the Cancer Genetics Program.  
-Represents the Cancer Genetics Program at various MGH Cancer Center Leadership meetings.  
-Represents Cancer Genetics Program at local and national genetics meetings.  
-Supports the developing Genomic Medicine Unit through building a network of genetic counseling services and a genomic risk clinic  
-Supports integrating genomics into practice at MGH institution wide.  
-Works collaboratively with other Genetics Programs at Mass General Brigham Healthcare.

**Massachusetts General Hospital Cancer Center** 6/12-12/20  
55 Fruit St.  
Boston, MA 02114  
*Director, Cancer Center Genetics Program*  
-Supervised genetic counseling staff  
-Supervised cancer genetics research staff  
-Performed all administrative duties of program  
-Provided supervision for Masters in Genetic Counseling candidates at Brandeis University  
-Performed all duties of Senior Genetic Counselor

**Massachusetts General Hospital Cancer Center** 9/05-5/12  
55 Fruit St.  
Boston, MA 02114  
*Program Manager, Cancer Genetics*  
*Senior Genetic Counselor*  
-Supervised genetic counseling staff  
-Supervised cancer genetics research staff  
-Performed administrative duties of program  
-Provided supervision for Masters in Genetic Counseling candidates at Brandeis University  
-Performed all duties of Senior Genetic Counselor

**Massachusetts General Hospital Cancer Center** 3/99-9/05  
55 Fruit St.  
Boston, MA 02114

*Senior Genetic Counselor*

- Performed administrative duties of program
- Provided supervision for Masters in Genetic Counseling candidates at Brandeis University
- Performed all duties of Genetic Counselor

**Massachusetts General Hospital Cancer Center**

4/97-3/99

55 Fruit St.

Boston, MA 02114

*Genetic Counselor*

- Provided cancer risk assessment for members of high risk breast, ovarian colon, and endocrine cancer families
- Provided predisposition testing counseling for cancer susceptibility genes
- Developed research and clinical protocols and instruments for predisposition testing for cancer susceptibility genes including BRCA1, BRCA2, p53, VHL, MSH2 and MLH1.
- Developed research protocols for investigating frequency of germline mutations in cancer susceptibility genes in control and disease populations

**Dana-Farber Cancer Institute**

5/96-5/98

44 Binney St.

Boston, MA 02115

*Genetic Counselor*

- Provided cancer risk assessment for members of high risk breast, ovarian colon, and endocrine cancer families
- Provided genetic counseling for long term survivors of pediatric cancer
- Provided predisposition testing counseling for cancer susceptibility genes
- Developed research and clinical protocols and instruments for predisposition testing for cancer susceptibility genes including BRCA1, BRCA2, p53, VHL, MSH2 and MLH1.

**Professional Experience**

**Professional Memberships**

National Society of Genetic Counselors (NSGC)  
NSGC Cancer SIG

**Professional Committees**

Member, ASCO Germline Mutation Testing in Breast Cancer Guideline Panel Consensus Panel, 2022-present.

Member, MGB Carrier Screening Oversight Committee, 2022-present.

Member, NSGC Advocacy Coordinating Committee. 2021-present.

Curriculum Vitae

Kristen Mahoney Shannon, MS, CGC

Page 4

- Member, MGH Genomic Implementation Advisory Board. 2019-present.
- Member, Li-Fraumeni Syndrome Association (LFSA) Genetic Counseling Advisory Group 2017-present.
- Member, MGH IHP Genetic Counseling Program Advisory Board. 2017-present.
- Member, NCCN Genetic Familial High-Risk Assessment: Breast and Ovarian Panel. 2008-present.
- Member, American Society of Clinical Oncology (ASCO) PLWC Advisory Board, 2006-present.
- Member, Lynch Syndrome Screening Network (LSSN). 2011-present.
- Member, NSGC Research Quality Outcomes Committee. 2018-2020.
- Member, NSGC Access and Service Delivery Committee. 2012-2015.
- Member, NSGC Public Policy Committee. 2010-2014.
- Member, Massachusetts Board of Licensure for Genetic Counselors. 2013-2015.
- Vice Chair, Massachusetts Board of Licensure for Genetic Counselors. 2011-2013.
- Secretary, Massachusetts Board of Licensure for Genetic Counselors. 2008-2011.
- Member, Partners Healthcare Genetics Confidentiality Steering Subcommittee. 2006 –2012.
- Member, National Society of Genetic Counselors Licensure Grants Committee. 2006-2008
- Co-Chair, Massachusetts Genetic Counselors Licensure Task Force. 2004-2008.
- Member, National Society of Genetic Counselors Billing & Reimbursement Task Force. 2003-2008.
- Member, Massachusetts Genetic Counselors Licensure Task Force. 2001-2008.
- Member, National Society of Genetic Counselors Professional Issues Committee. 1996-2008.
- Member, National Society of Genetic Counselors Abstract Committee. 2003-2006.
- Member, American Society of Human Genetics Abstract Committee. 2004.
- Member, NSGC Region I Annual Education Conference Planning Committee, 2000-2005.
- Chair, National Society of Genetic Counselors Professional Issues Committee, 2001-2003.
- Co-Chair, Cancer Genetics Committee, New England Regional Genetics Group (NERGG) 1998-2003.
- Co-Chair, Practice Issues Committee of the National Society of Genetic Counselors Cancer Special Interest Group. 2000-2003.
- Member, National Society of Genetic Counselors Billing and Reimbursement Ad Hoc Committee, 2001-2003.
- Co-Chair, Notebook Committee, National Society of Genetic Counselors' Short Course #3, "Cancer Genetic Counseling: A New Era Unfolds". 1997.

Member, Abstracts Committee, National Society of Genetic Counselors' Annual Education Committee. 2001.

Member, Partners HealthCare System Task Force On Genetics. 2000-2002.

Member, Brandeis University Genetic Counseling Program Clinical Non-Didactic Curriculum Committee (CNDCC), 2001-2008.

### **Other Professional Activities**

Reviewer, Journal of Medical Internet Research, 2021-present.

Reviewer, Journal of Genetic Counseling, 2004-2007, 2015-present.

Reviewer, Genetics in Medicine. 2017-present

NSGC Liaison to Health Professions Network (HPN), 2004-2009.

Reviewer, The American Journal of Obstetrics and Gynecology, 2003-2008.

## **Publications**

### **Textbook**

Schneider, K. A., Chittenden, A., & **Shannon, K. M.** (2023). Counseling About Cancer: Strategies for Genetic Counseling (4th ed.). Wiley. ISBN# 978-1119466468

### **Peer Reviewed Manuscripts**

Farmer MB, Bonadies DC, Pederson HJ, Mraz KA, Whatley JW, Darnes DR, Denton JJ, De Rosa D, Heatherly A, Kenney J, Lane K, Paul D, Pelletier RC, **Shannon KM**, Williams D, Matloff ET. Challenges and Errors in Genetic Testing: The Fifth Case Series. *Cancer J* 2021; 27:417-422.

McDuff SGR, Bellon JR, **Shannon KM**, Gadd MA, Dunn S, Rosenstein BS, Ho AY. ATM Variants in Breast Cancer: Implications for Breast Radiotherapy Treatment Recommendations. *Int J Radiat Oncol Biol Phys.* 2021 Feb 2;. doi: 10.1016/j.ijrobp.2021.01.045.

Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, Karlan BY, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G, Senter-Jamieson L, **Shannon KM**, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA. Genetic/Familial High-Risk Assessment: Breast,

Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2021 Jan 6;19(1):77-102.

**Shannon KM**, Emmet MM, Rodgers LH, Wooters M, Seidel ML. Transition to telephone genetic counseling services during the COVID-19 pandemic. *J Genet Couns*. 2020 Dec 4;. doi: 10.1002/jgc4.1365. [Epub ahead of print]

Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, **Shannon KM**, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SD. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. *J Natl Compr Canc Netw*. 2020

Isakoff, SJ, Lehman, CD, **Shannon, KM**, Basnet, KM. Case 7-2020: A 52-Year-Old Man with a Mass in the Left Breast. *N Engl J Med*, 2020;382:856-64.

Alimena S, Scarpetti L, Blouch EL, Rodgers L, **Shannon KM**, delCarmen MG, Goodman AK, Growdon W, Eisenhauer EL, Sisodia RC. Factors associated with referral and completion of genetic counseling in women with epithelial ovarian cancer. *International Journal of Gynecologic Cancer* Published Online First: 23 May 2020. doi: 10.1136/ijgc-2019-001168

Adar T, Friedman M, Rodgers LH, **Shannon KM**, Zukerberg LR, Chung DC. Gastric cancer in Lynch syndrome is associated with underlying immune gastritis. *J Med Genet*. 2019 Dec;56(12):844-845.

Daly M, Artomov M, Joseph V, Tiao G, Thomas T, Schrader KI, Klein S, Kiezun A, Gupta N, Margolin L, Stratigos A, Kim I, **Shannon K**, Ellisen L, Haber D, Getz G, Tsao H, Lipkin S, Altshuler D, and Offit K. Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes. *EJHG*. 2019 May;27(5):824-828.

Patel D, Blouch EL, Rodgers-Fouché LH, Emmet MM, **Shannon KM**. Finding a Balance: Reconciling the Needs of the Institution, Patient, and Genetic Counselor for Optimal Resource Utilization. *J Genet Couns*. 2018. 27:1318-1327.

Adar T, Rodgers LH, **Shannon KM**, Yoshida M, Ma T, Mattia A, Lauwers GY, Iafrate AJ, Hartford NM, Oliva E, Chung DC. Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. *Cancer*. 2018 Aug 1;124(15):3145-3153

Underhill ML, Blonquist TM, Habin K, Lundquist D, **Shannon K**, Robinson K, Woodford M, Boucher J. A state-wide initiative to promote genetic testing in an underserved population. *Cancer Medicine*. (2017) Jul;6(7):1837-1844.

Madlensky L, Trepanier AM, Cragus D, Lerner B, **Shannon KM**, Zierhut H. A rapid systemic review of outcomes studies in genetic counseling. *J Genet Couns* (2017) Jun;26(3):361-378.

Chung D, Adar T, Rodgers L, **Shannon KM**, Yoshida M, Ma T, Mattia A, Lauwers G, and Iafrate A. A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome. *Modern Pathology*. (2017) Mar;30(3):440-447

Zierhut HA, **Shannon KM**, Cragun DL, Cohen S. Elucidating Genetic Counseling Outcomes from the Perspective of Genetic Counselors. *J Genet Counsel* (2016) 25: 993-101.

Bartosch C, Pires-Luís AS, Meireles C, Baptista M, Gouveia A, Pinto C, **Shannon KM**, Jerónimo C, Teixeira MR, Lopes JM, Oliva E. Pathologic Findings in Prophylactic and Nonprophylactic Hysterectomy Specimens of Patients With Lynch Syndrome. *Am J Surg Pathol*. 2016 Sep;40(9):1177-91.

Soura E, Eliades PJ, **Shannon K**, Stratigos AJ, Tsao H. Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling. *J Am Acad Dermatol*. 2016 Mar;74(3):411-20; quiz 421-2.

Soura E, Eliades PJ, **Shannon K**, Stratigos AJ, Tsao H. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. *J Am Acad Dermatol*. 2016 Mar;74(3):395-407; quiz 408-10.

Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, **Shannon KM**, Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. *J Natl Compr Canc Netw*. 2016 Feb;14(2):153-62.

Underhill ML, Habin KR, **Shannon KM**. Perceptions of Cancer Risk, Cause, and Needs in Participants from Low Socioeconomic Background at Risk for Hereditary Cancer. *Behav Med*. 2016 Jan 25:1-9.

Zierhut HA, **Shannon KM**, Cragun DL, Cohen SA. Elucidating Genetic Counseling Outcomes from the Perspective of Genetic Counselors. *J Genet Couns*. 2016 Jan 19. [Epub ahead of print] PubMed PMID: 26781258.

Desmond A, Kurian AW, Gabree M, Mills M, Anderson MJ, Kobayashi Y, Horick N, Yang S, **Shannon KM**, Tung N, Ford JM, Lincoln SE, Ellisen LE. Clinical actionability of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment. *JAMA Oncology*. 2015 Oct 1;1(7):943-51.

Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom

PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, **Shannon KM**, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R, National comprehensive cancer network. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. *J Natl Compr Canc Netw*. 2014 Sep;12(9):1326-38.

Pilarski R, Burt R, Kohlman W, Pho L, **Shannon KM**, Swisher E. Cowden syndrome and the PTEN Hamartoma Tumor syndrome: systematic review and revised diagnostic criteria. *J. Natl. Cancer Inst*. 2013 105: 1607-1616.

Yurgelun MB, Mercado R, Rosenblatt M, Dandapani M, Kohlmann W, Conrad P, Blanco A, **Shannon KM**, Chung DC, Terdiman J, Gruber SB, Garber JE, Syngal S, Stoffel E. Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. *Gynceol Oncol* 127(3): 544-51, 2012.

**Shannon KM** and Chittenden AB. Testing by Disease Site: Breast. *Cancer J*. 18(4):310-9, 2012.

**Shannon KM**, Rodgers LH, Patel D, Chan-Smutko G, Gabree M, Ryan PD. Which BRCAanalysis patients need BART testing? *Cancer Genet*. 204(8): 416-22, 2011.

Brierley K, Campfield D, Ducaine W, Dohany L, Donenberg T, **Shannon KM**, Schwartz R, Matloff E. Should non-genetics providers perform their own cancer genetic counseling and testing? Case reports from the front line. *Conn Medicine*. 2010.

Stoffel EM, Mercado RC, Kohlmann W, Ford B, Grover S, Conrad P, Blanco A, **Shannon KM**, Powell M, Chung DC, Terdiman J, Gruber SB and Syngal S. Prevalence and Predictors of Appropriate Colorectal Cancer Surveillance in Lynch Syndrome. *Am J Gastroenterol*. 105(8):1851-60, 2010.

Manne SL, Meropol NJ, Weinberg DS, Vig H, Ali-Khan Catts Z, Manning C, Ross E, **Shannon KM**, and Chung DC. Facilitating Informed Decisions Regarding Microsatellite Instability Testing Among High-Risk Individuals Diagnosed With Colorectal Cancer. *JCO*. 28(8):1366-1372. 2010.

Daly M B, Axilbund J E, Buys S, Crawford B, Farrell C D, Friedman S, Garber J E, Goorha S, Gruber S B, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom P K, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G. **Shannon K M**, Smith J R, Swisher E, Weitzel J N, National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. *J Natl Compr Canc Netw*. 8(5): 562-94, 2010.

Vogel K and **Shannon KM**. Li Fraumeni Syndrome. *Community Oncology* 6(11): 507-518. 2009.

McKinnon W, Banks K, Skelly J, Kohlmann W, Bennett R, **Shannon KM**, Larson-Haidle J, Ashakaga T, Weitzel JN, Wood M. Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals: Insurance outcomes. *Fam Cancer*. 8(4): 363-369, 2009.

Zhang J, Song Y, Brannigan BW, Wahrer DCR, Schiripo TA, Haserlat SM, **Shannon KM**, Garber JE, Freedman ML, Henderson BE, Altshuler D, Sgroi DC, Haber DA, and Bell DW. Prevalence and functional analysis of sequence variants in the ATR cofactor Claspin (CLSPN). *Molecular Cancer Research*. 7(9):1510-6, 2009.

Grover S, Stoffel E, Mercado R, Ford B, Kohlmann W, **Shannon KM**, Conrad P, Blanco A, Terdiman J, Gruber S, Chung D, Syngal S. Colorectal Cancer Risk Perception on the Basis of Genetic Test Results in Individuals at Risk for Lynch Syndrome. *J Clin Oncol* 27(24): 3981-3986, 2009.

Chan-Smutko G, Patel D, **Shannon KM**, Ryan PD. Professional challenges in cancer genetic testing: who is the patient? *Oncologist*. 13:232-38, 2008.

Stoffel EM, Ford B, Mercade RC, Punglia R, Kohlmann W, Conrad P, Blanco A, **Shannon KM**, Powell M, Gruber S, Terdiman J, Chung D, Syngal S. Sharing Genetic Test Results in Lynch Syndrome: Communication with Close and Distant Relatives. *Clinical Gastroenterol Hepatol* 6(3):333-8, 2008.

Manne SM, Chung D, Weinberg DS, Vig HS, Catts Z, Cabral MK, **Shannon KM**, Meropol NJ. Knowledge and Attitudes about Microsatellite Instability Testing Among High-Risk Individuals Diagnosed with Colorectal Cancer. *Cancer Epidemiology Biomarkers & Prevention* 16(10): 2110-2117, 2007.

Herraiz M, Barbesino G, Faquin W, Chan-Smutko G, Patel D, **Shannon KM**, Daniels GH, Chung DC. Prevalence of thyroid cancer in the Familial Adenomatous Polyposis syndrome and the role of screening ultrasound examinations. *Clinical Gastroenterol Hepatol* 5(3):367-73, 2007.

Matloff E, **Shannon KM**, Moyer A, Col N. Should Menopausal Women at Increased Risk for Breast Cancer Use Tamoxifen, Raloxifene or Hormone Therapy?: A Framework for Personalized Risk Assessment and Counseling. *J Cancer Education* 2007, Vol. 22, No. 1, Pages 10-14.

**Shannon KM**, Smutko GC, Niendorf KB, Ryan PD. Uptake of BRCA1 Rearrangement Panel Testing in Individuals Previously Tested for BRCA1/2 Mutations. *Genetics in Medicine* 8(12): 740-745, 2006.

Matloff E, **Shannon KM**, Niendorf KB, Moyer A, Col, N. Healthy Women with a Family History of Breast Cancer: Impact of a Tailored Genetic Counseling Intervention on Risk Perception, Knowledge, and Menopausal Therapy Decision-Making. *J Women's Health* 15 (7): 843-856, 2006.

Jo WS, Bandipalliam P, **Shannon KM**, Niendorf KB, Chan-Smutko G, Syngal S, Chung DC. Polyp number and family history are not reliable predictors of germline MYH mutations. *Clinical Gastroenterology and Hepatology* 3:1022-1028, 2005.

Chung DC, Mino M, **Shannon KM**. Case 34-2003: A 45-Year-Old Woman with a Family History of Colonic Polyps and Cancer. *NEJM* 349(18): 1750-1760, 2003.

Ryan PD, Haber DA, **Shannon KM**, Smith BL, Fan MJ. Case 28-2003: A 51-Year-Old Premenopausal Woman with Newly Diagnosed Breast Cancer and a Strong Family History of Breast Cancer. *NEJM* 349(11):1076-1082, 2003.

**Shannon KM**, Lubratovich ML, Finkelstein DM, Smith BL, Powell SN, Seiden MV. Model-Based Predictions of BRCA1/2 Mutation Status in Breast Cancer Patients at an Academic Medical Center. *Cancer* 94(2): 305-313, 2002.

Niendorf KB, **Shannon KM**. The Role of Genetic Testing and Impact on Patient Care. *Arch Dermatol* 137(11):1515-1519, 2001.

Lee SB\*, Kim SH\*, Bell DW\*, Wahrer DCR, Schiripo TA, Jorzak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, **Shannon KM**, Harlow E, Haber DA. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. *Cancer Res* 61: 8062-8067, 2001.

Penson RT, Seiden MV, **Shannon KM**, Lubratovich ML, Roche M, Chabner BA, Lynch TJ. Communicating Genetic Risk: Pros, Cons, and Counsel. *The Oncologist*. 2000;5:152-161.

Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, **Shannon KE**, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. *Science*. 286(5449):2528-31, 1999.

**Shannon KE**, Gimm O, Dralle H, and Eng C. Germline V804M mutation in the *RET* proto-oncogene in two apparently sporadic cases of MTC presenting in the seventh decade of life. *J Endo Genet* 1: 39-45, 1999.

Nichols KE, Levitz S, **Shannon KE**, Wahrer DCR, Bell DW, Chang G, Hegde S, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA and Diller L. Heterozygous ATM mutations do not contribute to radiation-induced malignancies in Hodgkin's Disease survivors. *J Clin Oncol* 17(4): 1259-1266, 1999.

Schneider KA, Kieffer SA, **Shannon KM**, Hiller EH, Chittenden AB. An Update on BRCA1: Molecular findings and clinical issues. *Genetic Resource* 11(2):5-9, 1998.

Penson RT, **Shannon KE**, Sharpless NE, and Seiden MV. Ovarian Cancer: An Update on Genetics and Therapy. *Comprehensive Therapy* 24(10): 477-487, 1998.

FitzGerald MG, Marsh DJ, Wahrer D, Bell D, **Shannon KE**, Ishioka C, Isselbacher KJ, Garber JE, Eng C, Haber DA. Germline mutations in *PTEN* are an infrequent cause of genetic predisposition to breast cancer. *Oncogene* 17: 727-731, 1998.

## Book Chapters

Chung D and **Shannon KM**. GI Cancer Genetics. In: Expert Clinical Perspective on Diagnosis and Management of Cancer (Edited by Syed Abutalib and Maurie Markman). Wiley. (*in press*).

**Shannon KM** and Chittenden AB. Breast Cancer Genetics and Risk Assessment. In: Breast Cancer Screening and Diagnosis Project (Shetty, ed.). Springer. (*in press*)

**Shannon KM** and Patel D. Assessment of family history, genetic counseling, and principles of genetic testing. In: MGH Guide to Clinical Cancer Genetics. Springer. 2010.

**Shannon KM** and Ryan PD. Identification of high risk patients. In: Multidisciplinary Approach in the Treatment of Breast Cancer. Eds. Taghian A, Smith BL, Erban J. Demos Medical Publishing. 2010.

Schneider, K, Branda, K, Chittenden, A, and **Shannon, K**: Cancer Genetics. In the Encyclopedia of Genomics, Proteomics and Bioinformatics. (Ed. Jorde LB, Little P, Dunn M, and Subramaniam S) John Wiley & Sons, Chichester, West Sussex UK.

[www.interscience.wiley.com/mrw/eggpb](http://www.interscience.wiley.com/mrw/eggpb). 2004.

**Shannon KM**, Niendorf KB, Ryan PD, Penson RT. Cancer Genetics. In: Facing Cancer. Eds. MA Sekeres and TA Stern. McGraw-Hill Companies, Inc. US. 2004.

Schneider KA, **Shannon KE**, Kieffer SK, Hiller EH, Chittenden AB. Cancer Genetic Counseling. In The Molecular Basis of Human Cancer. Eds. WB Coleman and GJ Tsongalis, Humana Press, Inc., Totana, NJ. 2001.